Agreement grants JH Health exclusive rights to use and distribute Atelerix’s portfolio of non-cryogenic preservation solutions in the region
Expands regional capabilities with funding for high-volume local manufacturing, as well as relevant regulatory filings and research collaborations
Strategic partnership enables access to new investment opportunities from Saudi sovereign funds
Newcastle, UK, 15 April 2026: Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it has established…
Sandwich, UK — 15 April 2026: International contract research organisation ChemPartner has officially opened its first European scientific hub at Discovery Park, Sandwich, Kent. The company works with the biopharmaceutical industry to efficiently and rapidly bring life-changing drugs to market.
Founded in Shanghai in 2002, ChemPartner has more than 2,000 employees globally, most of whom are based in Asia. The company currently has seven UK employees, many of whom work hybrid, and is actively recruiting for a Senior Scientist to be based at Discovery Park.
ChemPartner’s Discovery Park facility…
ELRIG Announces Inaugural US Drug Discovery Conference
Free-to-attend event takes place at Pfizer in Cambridge, MA from 16–17 June
Drug Discovery USA 2026 to focus on emerging multifunctional small molecule and biologic approaches to drug difficult targets
Cambridge, UK, 14 April 2026: ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, today announced the launch of Drug Discovery USA 2026. The inaugural event, taking place at Pfizer in Cambridge, MA from 16–17 June, offers the drug discovery communities in Europe and the US the…
Amsbio reports how researchers at the Graduate School of Medicine, Kyoto University (Japan) have cultured patient-derived colorectal cancer cells in 3D using their MatriMix 511 extracellular matrix (ECM).
In this study** the researchers demonstrated that MatriMix supported robust cancer organoid formation, and that the organoids retained biologically relevant differences between tumour stages. By comparison, alternative matrices evaluated showed limited or no metastatic marker expression. The researchers concluded that MatriMix offers the ability to…
In the race to bring new therapeutics to market, the biggest hurdles aren’t just scientific—they’re operational. Fragmented data and information fatigue can slow down even the most promising pipelines.
To help biotech leaders bridge these gaps, Digital Science has launched a comprehensive resource hub focused on Advancing R&D Excellence. This suite of resources provides the framework needed to make confident, evidence-based decisions at every stage of discovery.
Inside the hub, you’ll find:
📘 The White Paper: A deep dive into "Structured Intelligence," exploring how AI is…
Tony JonesCEO, One Nucleus
Springing Forward in 2026 As the temperatures rise, flowers begin to bloom, and the deal flow reports keep coming; it feels like biotech may have a spring in its step. April storms and showers to dampen the mood are circling for many still; however, it is far from a universal bed of roses.
Thirty-six investment rounds were announced during Q1/2026, amounting to nearly £0.5Bn venture investment across the London and Cambridge areas alone in the sector. Notable rounds were secured by Mestag Therapeutics, Nuclera, Tenpoint…
Enables expression of active GPCRs in 48 hours
Panel supports screening to scale-up on eProtein Discovery
Cambridge, UK, and Boston MA, USA, 30 March 2026: Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs). Building on the eProtein Discovery™ membrane protein workflow capabilities1, the nanodisc panel allows membrane protein scientists focusing on GPCR research to identify optimal membrane environments and increase production of…
Cambridge Wide Open Week (CWOW) returns 11–19 June 2026, sharing the spirit and buzz of the week-long, interactive festival with Oxford and London for the very first time. The Cambridge-Oxford-London corridor is widely regarded as one of the most productive life sciences clusters in the world, home to hundreds of biotechnology companies, globally recognised research institutions and a rapidly expanding venture capital ecosystem. Building on last year’s event, which attracted more than 4,000 attendees across 25+ venues and 200+ sessions, CWOW 2026 will convene investors,…
by Alicia Gailliez, Business Development Manager, One Nucleus
Breakthroughs are accelerating across therapeutics, data platforms, regulatory systems and business models. Yet challenges remain in how we develop and scale innovation within an increasingly complex landscape. Addressing these challenges requires collaboration across the life science ecosystem.
ON Helix brings together this breadth and diversity, connecting biotech innovators, pharma, academia, service providers and investors to create an environment for meaningful peer-to-peer learning and deal-making. It is through these…
by Alicia Gailliez, Business Development Manager, One Nucleus
The winners of the Boston Bootcamp 2026 have been announced! Congratulations to ExpressionEdits, Monument Therapeutics, Profionics, and Stick Therapeutics. These four standout companies impressed a panel of esteemed UK and US judges during the online presentation session on 24 February, where 16 companies each pitched their vision in a 5-minute slot.
With the competition now moving ever closer towards the Boston visit (27–30 April), the focus shifts to preparatory sessions with Bootcamp supporters and sponsors. These sessions are…